KPV

KPV in the Published Literature

UKPWritten and published by UK Peptides1 min readUpdated 3 cited sources

The short answer

PubMed indexes roughly 34 records on KPV's anti-inflammatory work. The literature is predominantly murine and cell culture, with the alpha-MSH parent literature providing broader context. There is no established human clinical programme.

Key facts

Indexed records
~34 on anti-inflammatory work
Dominant evidence
Murine models, cell culture
Key model paper
Kannengiesser 2008 (PMID 18092346)
Delivery work
Xiao 2017 (PMID 28143741)
Parent context
Luger 2003, Brzoska 2010
Clinical trials
None established

A small literature with a clear shape

Around 34 indexed records is modest, smaller than Selank's 135, far smaller than DSIP's 519. What it lacks in volume it makes up in consistency: the work runs from mechanism through disease models to delivery, which is a coherent trajectory rather than scattered observations.

The parent literature is larger and relevant

Alpha-MSH has a substantially bigger literature, and Luger's 2003 review in the Annals of the New York Academy of Sciences and Brzoska's 2010 chapter both cover the anti-inflammatory arm. Much of it concerns the whole hormone rather than the tripeptide, so the same read-across caution applies here as for thymosin beta-4 and its 7-residue fragment.

Research material referenced

KPV 10mg, third-party HPLC tested

Buy KPV · £28.99

Searching it

KPV alone returns a mix, since the abbreviation is short and collides with unrelated terms, the same problem that puts an organic acid at the top of a PubChem search. Combining it with peptide or with anti-inflammatory narrows it usefully. Lys-Pro-Val finds chemical records; alpha-MSH finds the parent literature.

What is absent

Human clinical trials. Independent replication across many groups. And a defined molecular target. NF-κB interference is described as an effect rather than mapped to a binding interaction. These gaps are ordinary for a compound at this stage rather than remarkable.

How it compares within this library

Less studied than BPC-157, which has a Phase 2 recruiting, or GHK-Cu with its decades of work. Better motivated than DSIP, whose central claim has never resolved. KPV sits in the middle: a clear rationale, a small consistent literature, and no human data.

Frequently asked questions

How large is the KPV literature?

Roughly 34 indexed records on the anti-inflammatory work, modest, but consistent in direction.

Are there clinical trials?

None established. The evidence is murine models and cell culture.

How should I search for it?

KPV alone collides with unrelated terms. Combine it with peptide or anti-inflammatory, and search Lys-Pro-Val for chemical records.

Continue researching

Related guides and reference material.

Primary sources & clinical trials

Published papers, trial registrations, regulator pages and company announcements. Links open the original.

Browse the wider literature

Live database searches, not fixed citations. Results change as new work is indexed.

UKP

Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).

Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.

Corrections log

More KPV articles

Research use only. The information above is provided for scientific and educational reference. Compounds referenced are not approved for human use and are supplied for in vitro research or reference-material purposes only. No efficacy, safety, or therapeutic claims are made.